Antigen Detection assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
基本信息
- 批准号:8883363
- 负责人:
- 金额:$ 67.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-06-15 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AbscessAcuteAdvanced DevelopmentAerosolsAffinityAlgorithmsAntibiotic TherapyAntibioticsAntigensArchivesAreaAustraliaAwardBacteriaBiological AssayBiological MarkersBlood typing procedureBuffersBurkholderia pseudomalleiCase StudyCenters for Disease Control and Prevention (U.S.)CharacteristicsClinicalCountryDetectionDevelopmentDiagnosisDiagnosticDiagnostic ReagentDiagnostic testsDiseaseEnzyme-Linked Immunosorbent AssayFeasibility StudiesGenetic VariationGoalsGoldGram-Negative BacteriaHealthHousingHumanImmunoassayIn VitroInfectionInternationalLaboratoriesLateralLeadLeftLibrariesMelioidosisMembraneModelingMonoclonal AntibodiesMorbidity - disease rateMusNational Institute of Allergy and Infectious DiseaseOrganPatientsPerformancePhasePolysaccharidesPreparationPrevalence StudyProductionPublic HealthPusReproducibilityResistanceSamplingSepsisSerumSiteSkin TissueSmall Business Technology Transfer ResearchSoilSpecificitySpecimenSputumSymptomsTestingThailandTropical DiseaseUrineValidationVariantWorkcost effectivecross reactivitydesigndiagnosis standardeffective therapyexperiencefield studyin vivomortalitypoint of carepre-clinicalpreclinical evaluationprototyperapid diagnosisscale upsoft tissue
项目摘要
DESCRIPTION (provided by applicant): Burkholderia pseudomallei is a Gram-negative bacterium that is the causative agent of melioidosis. The bacterium causes significant morbidity and mortality in tropical regions and endemic areas are expanding. Melioidosis is difficult to trea and diagnose due to the fact that B. pseudomallei is resistant to common antibiotics and symptoms are non-specific. Mortality rates reach 45% and 20% in Thailand and Australia respectively, even with antibiotic treatment. Currently, there is no validated diagnostic product for the diagnosis of melioidosis. Culturing of patient samples is the "gold standard" for diagnosis; however this can take 3-7 days. Our goal is to develop a rapid point-of-care lateral flow immunoassay (LFI) for the detection of the B. pseudomallei capsular antigen (CPS) directly from patient samples. Phase I STTR Specific Aims focused on producing a library of anti-CPS monoclonal antibodies (mAbs), optimizing the LFI components and sample preparation, and performing a feasibility study on archived melioidosis patient samples. The objectives of this Phase II application is advanced development and validation of the prototype AMD LFI that incorporates a higher affinity CPS mAb. By completing these goals we hope to produce an optimized LFI that possesses sensitivity equal to or greater than culturing of patient samples. To achieve these goals we have established an experienced team. A strong partnership exists between Dr. AuCoin's laboratory and InBios International that has led to the development of an encouraging prototype LFI. In addition, both groups will work closely with experts in endemic areas (Thailand and Australia) who will be conducting a large preclinical evaluation of the LFI with different patient sample types.
性状(由申请方提供):类鼻疽伯克霍尔德菌是一种革兰氏阴性菌,是类鼻疽病的病原体。这种细菌在热带地区引起显著的发病率和死亡率,流行地区正在扩大。由于B。类鼻疽对普通抗生素有抗药性,症状没有特异性。在泰国和澳大利亚,即使使用抗生素治疗,死亡率也分别达到45%和20%。目前,没有经过验证的诊断产品用于诊断类鼻疽。患者样本的培养是诊断的“金标准”;然而,这可能需要3-7天。我们的目标是开发一种快速的床旁侧流免疫测定(LFI)检测的B。从患者样品中直接提取类鼻疽荚膜抗原(CPS)。I期STTR特定目标侧重于生产抗CPS单克隆抗体(mAb)文库,优化LFI组分和样品制备,并对存档的类鼻疽患者样品进行可行性研究。该II期申请的目的是对包含更高亲和力CPS mAb的原型AMD LFI进行高级开发和验证。通过完成这些目标,我们希望产生一种优化的LFI,其灵敏度等于或大于患者样本的培养。为了实现这些目标,我们组建了一支经验丰富的团队。AuCoin博士的实验室和InBios International之间存在着强大的合作伙伴关系,这导致了令人鼓舞的LFI原型的开发。此外,这两个小组将与流行地区(泰国和澳大利亚)的专家密切合作,他们将使用不同的患者样本类型对LFI进行大型临床前评估。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David P AuCoin其他文献
David P AuCoin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David P AuCoin', 18)}}的其他基金
Enrichment and validation of urine and serum-specific antigens from acute Lyme disease patient samples
急性莱姆病患者样本中尿液和血清特异性抗原的富集和验证
- 批准号:
10539304 - 财政年份:2021
- 资助金额:
$ 67.35万 - 项目类别:
Enrichment and validation of urine and serum-specific antigens from acute Lyme disease patient samples
急性莱姆病患者样本中尿液和血清特异性抗原的富集和验证
- 批准号:
10373787 - 财政年份:2021
- 资助金额:
$ 67.35万 - 项目类别:
Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)
用于早期诊断埃博拉病毒病 (EVD) 的即时抗原检测分析
- 批准号:
9910131 - 财政年份:2020
- 资助金额:
$ 67.35万 - 项目类别:
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
人类和非人类伯氏疏螺旋体诊断生物标志物的鉴定
- 批准号:
8783365 - 财政年份:2014
- 资助金额:
$ 67.35万 - 项目类别:
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
人类和非人类伯氏疏螺旋体诊断生物标志物的鉴定
- 批准号:
8892078 - 财政年份:2014
- 资助金额:
$ 67.35万 - 项目类别:
Antigen Detection assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
- 批准号:
9084470 - 财政年份:2012
- 资助金额:
$ 67.35万 - 项目类别:
Antigen Detection Assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
- 批准号:
8490302 - 财政年份:2012
- 资助金额:
$ 67.35万 - 项目类别:
Antigen Detection Assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
- 批准号:
8394825 - 财政年份:2012
- 资助金额:
$ 67.35万 - 项目类别:
Antigen Detection assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
- 批准号:
8780682 - 财政年份:2012
- 资助金额:
$ 67.35万 - 项目类别:
Antigenemia immunoassay for point of care dianostic melioidosis
抗原免疫分析用于诊断类鼻疽病的护理点
- 批准号:
8260262 - 财政年份:2011
- 资助金额:
$ 67.35万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 67.35万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 67.35万 - 项目类别:
Operating Grants